SBIR-STTR Award

Medications for the Treatment of Alcohol Abuse and Dependence and Relapse
Award last edited on: 1/18/2024

Sponsored Program
SBIR
Awarding Agency
NIH : NIAAA
Total Award Amount
$2,072,092
Award Phase
2
Solicitation Topic Code
273
Principal Investigator
Lawrence Snell

Company Information

Lohocla Research Corporation

12705 East Montview Boulevard Suite 350
Aurora, CO 80045
   (303) 645-3788
   inquiry@lohocla.com
   www.lohocla.com
Location: Single
Congr. District: 06
County: Adams

Phase I

Contract Number: 1R43AA009930-01A1
Start Date: 7/1/1995    Completed: 12/31/1995
Phase I year
1995
Phase I Amount
$78,375
Chronic ethanol ingestion results in neurodegeneration with loss of neurons, glial proliferation and enlargements in ventricular and subarachnoid space. Work from our laboratories has demonstrated that chronic ethanol administration to animals produces an up-regulation of the excitatory N-methyl-D-aspartate (NMDA) subtype of glutamate receptor in brain. We have recently implicated the NMDA receptor system in induction of excitotoxic damage to various neurons of the brain during ethanol withdrawal. We will test a series of compounds for their effectiveness in protecting neurons of the cerebellum and cerebral cortex, grown in culture, against ethanol withdrawal induced excitotoxic damage. We will assess the effectiveness of a novel NMDA receptor channel blocker, (+)-5- aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine(ADCI), which we have previously shown to be an excellent agent for reducing behavioral hyperexcitability (tremor, convulsions) during ethanol withdrawal in animals. We will also test antagonists, i.e.,: cycloleucine, and low efficacy partial agonists i.e.,; 1-neuroprotective actions in our cell culture model of ethanol withdrawal excitotoxicity. Finally, we will test a series of gangliosides, including GM1 and GT1b, since these compounds have been touted to protect against glutamate-induced excitotoxicity without compromising the initial neurotransmission related events accompanying NMDA receptor stimulation. Our studies will generate an understanding of which classes of compounds are most effective for preventing ethanol withdrawal excitotoxicity and provide a basis for in vivo studies with animals in Phase II of the SBIR program.National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Phase II

Contract Number: 2R44AA009930-02A1
Start Date: 7/1/1995    Completed: 8/31/1999
Phase II year
1997
(last award dollars: 2009)
Phase II Amount
$1,993,717

There is no text on file for this abstract.Thesaurus termsNMDA receptor, drug addiction antagonist, drug screening /evaluation, drug withdrawal, neuroprotectant, neurotransmitter antagonist alcoholism /alcohol abuse chemotherapy, anticonvulsant, brain injury, chemical structure /function, chemical structure function, chemical synthesis, drug design /synthesis /production, kynurenate, nonhuman therapy evaluation, pharmacokinetics high performance liquid chromatography, immunochemistry, laboratory mouse, western blottingNational Institute on Alcohol Abuse and Alcoholism (NIAAA)